Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects

Regulatory Peptides

Volumn 179, Issue 1-3, 2012, Pages 77-83

  Keller, Jutta ^a   Trautmann, Michael E ^b   Haber, Harry ^e   Tham, Lai San ^c   Hunt, Tamsin ^d   Mace, Kenneth ^e   Linnebjerg, Helle ^d  

^a ISRAELITISCHES KRANKENHAUS   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c PharmaNet/i3   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Ejection fraction; Glucagon like peptide 1; Ultrasonography

Indexed keywords

CHOLECYSTOKININ; EXENDIN 4; PLACEBO;

ADULT; ARTICLE; BILE DUCT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOGRAPHY; GALLBLADDER EMPTYING; HUMAN; HUMAN EXPERIMENT; NAUSEA; NORMAL HUMAN; PANCREAS DUCT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; AGED; BILE DUCTS; BLOOD GLUCOSE; CHOLECYSTOKININ; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FASTING; FEMALE; GALLBLADDER; GALLBLADDER EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; ORGAN SIZE; PANCREATIC DUCTS; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 84866701959     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.08.005     Document Type: Article

References (39)

1. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
2. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
3. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
4. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
5. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281:E155-E161.
6. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
7. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr Med Res Opin 2008, 24:275-286.
8. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
9. Deane A.M., Nguyen N.Q., Stevens J.E., Fraser R.J., Holloway R.H., Besanko L.K., et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010, 95:215-221.
10. Hellström P.M., Näslund E., Edholm T., Schmidt P.T., Kristensen J., Theodorsson E., et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008, 20:649-659.
11. Linnebjerg H., Park S., Kothare P.A., Trautmann M.E., Mace K., Fineman M., et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008, 151:123-129.
12. Nauck M.A., Kemmeries G., Holst J.J., Meier J.J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60:1561-1565.
13. Hellström P.M. GLP-1 playing the role of a gut regulatory compound. Acta Physiol (Oxf) 2011, 201:151-156.
14. Parulekar S.G. Ultrasonic evaluation of the pancreatic duct. J Clin Ultrasound 1980, 8:457-463.
15. Dodds W.J., Groh W.J., Darweesh R.M., Lawson T.L., Kishk S.M., Kern M.K. Sonographic measurement of gallbladder volume. AJR Am J Roentgenol 1985, 145:1009-1011.
16. Barr R.G., Kido T., Grajo J.R. Comparison of sonography and scintigraphy in the evaluation of gallbladder functional studies with cholecystokinin. J Ultrasound Med 2009, 28:1143-1147.
17. Barr R.G., Agnesi J.N., Schaub C.R. Acalculous gallbladder disease: US evaluation after slow-infusion cholecystokinin stimulation in symptomatic and asymptomatic adults. Radiology 1997, 204:105-111.
18. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellström P.M. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998, 43:2284-2290.
19. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellström P.M. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 1998, 102:764-774.
20. Rotondo A., Amato A., Lentini L., Baldassano S., Mule F. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 2011, 32:60-64.
21. Gullo L., Bolondi L., Scarpignato C., Priori P., Casanova P., Labo G. Effect of somatostatin and thyrotropin-releasing hormone on cholecystokinin-induced gallbladder emptying. Dig Dis Sci 1986, 31:1345-1350.
22. Brubaker P.L., Drucker D.J. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002, 8:179-188.
23. Lock G., Kammerl M., Schlottmann K., Bregenzer N., Holstege A., Schölmerich J. Gallbladder motility in healthy volunteers: effects of age, gender, body mass index, and hair color. Hepatogastroenterology 2003, 50:1232-1235.
24. Marzio L., Falcucci M., Ciccaglione A.F., Malatesta M.G., Lapenna D., Ballone E., et al. Relationship between gastric and gallbladder emptying and refilling in normal subjects and patients with H. pylori-positive and -negative idiopathic dyspepsia and correlation with symptoms. Dig Dis Sci 1996, 41:26-31.
25. Horrow M.M. Ultrasound of the extrahepatic bile duct: issues of size. Ultrasound Q 2010, 26:67-74.
26. European Medicines Agency Summary of product characteristics Accessed. http://p://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf.
27. Kothare P.A., Linnebjerg H., Isaka Y., Uenaka K., Yamamura A., Yeo K.P., et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 2008, 48:1389-1399.
28. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
29. Byetta prescribing information Accessed. http://documents.byetta.com/Byetta_PI.pdf.
30. Linnebjerg H., Seger M., Kothare P.A., Hunt T., Wolka A.M., Mitchell M.I. A thorough QT study to evaluate the effects of singledose exenatide 10μg on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther 2011, 49:594-604.
31. Degn K.B., Brock B., Juhl C.B., Djurhuus C.B., Grubert J., Kim D., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
32. Rayner C.K., Samsom M., Jones K.L., Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371-381.
33. Pinelli N.R., Jantz A., Smith Z., Abouhassan A., Ayar C., Jaber N.A., et al. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. J Clin Pharmacol 2011, 51:165-172.
34. Reddy S., Park S., Fineman M., Jay L., Carter M., Reynolds M., et al. Clinical pharmacokinetics of exenatide in patients with type 2 diabetes. AAPS J 2005, 7. AAPS2005-001182.
35. Fraquelli M., Pagliarulo M., Colucci A., Paggi S., Conte D. Gallbladder motility in obesity, diabetes mellitus and coeliac disease. Dig Liver Dis 2003, 35(Suppl. 3):S12-S16.
36. Hahm J.S., Park J.Y., Park K.G., Ahn Y.H., Lee M.H., Park K.N. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol 1996, 91:2391-2394.
37. Kayacetin E., Kisakol G., Kaya A., Akpinar Z. Real-time sonography for screening of gallbladder motility in diabetic patients: relation to autonomic and peripheral neuropathy. Neuro Endocrinol Lett 2003, 24:73-76.
38. Pazzi P., Scagliarini R., Gamberini S., Pezzoli A. Review article: gall-bladder motor function in diabetes mellitus. Aliment Pharmacol Ther 2000, 14(Suppl. 2):62-65.
39. Shaffer E.A. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006, 20:981-996.